Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review
Open Access
- 16 August 2021
- journal article
- review article
- Published by Springer Nature in BioDrugs
- Vol. 35 (5) , 547-561
Abstract
Background Biosimilars are expected to decrease growing health care expenditures. Given that uptake of biosimilars has been modest, automatic substitution has been suggested to increase their use, but the practice is not yet allowed or implemented in many jurisdictions. Methods A systematic review was performed by searching databases Scopus, Medline (Ovid), CINAHL, and Web of Science. Peer-reviewed, original studies written in English and published during the period January 1, 2006 to April 24, 2021 reporting any interventions, pilots or any other studies including experiences or perceptions of any relevant stakeholders on automatic substitution of biologics were included without limitation by setting or geography. The quality of the included studies were evaluated by pre-determined criteria. Results Altogether, 27 studies fulfilled the inclusion criteria, of which 23 were surveys, and four semi-structured interviews reporting mainly stakeholders’ perceptions on automatic substitution. Most of the studies (56%, 15/27) were from Europe. Studies were conducted among prescribers (n = 12), pharmacists (n = 5), patients (n = 4), payers (n = 1), and mixed stakeholders (n = 5). The primary objective of the majority (81%, 22/27) of the studies was to investigate some other biosimilar topic than automatic substitution. The reported perceptions of substitution were mainly negative. Studies evaluating risks, safety or effectiveness, or reporting real-life experiences of biologic substitution were lacking except one intervention and two prospective risk management studies. The overall quality of the studies was low to moderate, and the results were not generalizable due to convenience sampling not representing the populations of interest, and low response rates. Conclusions The current research evidence on the automatic substitution of biologics is scarce and of low to moderate quality, reflecting low stakeholder knowledge and their cautious attitude towards biosimilars. The safe and efficient implementation of automatic substitution requires well-designed practices, pilot studies, and evolving legislation.Keywords
Funding Information
- University Pharmacy, Helsinki, Finland (2015-2016)
- University of Helsinki including Helsinki University Central Hospital
This publication has 63 references indexed in Scilit:
- Time Series Analysis on the Impact of Generic Substitution and Reference Pricing on Antipsychotic Costs in FinlandValue in Health, 2015
- The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic ReviewApplied Health Economics and Health Policy, 2015
- Update on US state legislation on biosimilars substitutionGenerics and Biosimilars Initiative Journal, 2015
- How to assess a survey report: a guide for readers and peer reviewersCanadian Medical Association Journal, 2015
- Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsClinical Rheumatology, 2015
- Barriers to market uptake of biosimilars in the USGenerics and Biosimilars Initiative Journal, 2014
- How to Read a Systematic Review and Meta-analysis and Apply the Results to Patient CareJAMA, 2014
- Biosimilars naming, label transparency and authority of choice – survey findings among European physiciansGenerics and Biosimilars Initiative Journal, 2014
- Barriers to the Uptake of Biosimilars and Possible Solutions: A Belgian Case StudyPharmacoEconomics, 2014
- Biosimilars—why terminology mattersNature Biotechnology, 2011